Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Newron Pharmaceuticals secures EUR 5.5 million through an investor group as part of up to EUR 38 million financing to support the ENIGMA-TRS Phase 3 program.
Newron Pharmaceuticals announced an investment of EUR 5.5 million from an investor group as part of a larger EUR 38 million financing. This funding will strengthen the company's financial position as it advances its ENIGMA-TRS Phase 3 program. The investor group initially subscribed to a total of EUR 15 million and is expected to contribute more in the future. The new shares will be listed on multiple exchanges starting today.
Company Information
Company
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd
Location
Milan, Lombardy, Italy
About
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. focused on pharmaceutical development.
Don't miss Newron Pharmaceuticals S.p.A. & EA Pharma Ltd's next move
Get an email the moment Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Newron Pharmaceuticals S.p.A. & EA Pharma Ltd's next move
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
MilanBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma